Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (DE:BO1)
FRANKFURT:BO1
Holding DE:BO1?
Track your performance easily
BO1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.84 - €7.82
Previous Close€7.07
Volume0.00
Average Volume (3M)778.00
Market Cap
€1.48B
Enterprise Value€1.47B
Total Cash (Recent Filing)$330.01M
Total Debt (Recent Filing)$327.36M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Feb 19, 2025EPS Estimate
-€0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding207,132,571
10 Day Avg. Volume16
30 Day Avg. Volume778
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-3.13
Price to Sales (P/S)3.71
Price to Cash Flow (P/CF)46.40
P/FCF Ratio46.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda-60.75
Forecast
1Y Price Target
€15.44Price Target Upside118.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
BioCryst News
PremiumCompany Announcements
BioCryst Pharmaceuticals Reports Strong Q3 2024 Results
PremiumCompany Announcements
BioCryst Announces Strong Q3 2024 Revenue GrowthOptions Prices
Currently, No data available
---
Ownership Overview
6.31% Insiders
17.52% Mutual Funds
34.51% Other Institutional Investors
24.63% Public Companies and
Individual Investors
BO1 FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was €3.84 and its highest was €7.82 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Currently, no data Available
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Feb 19, 2025 which is in 60 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Nov 04, 2024. The company reported -€0.068 earnings per share for the quarter, missing the consensus estimate of -€0.067 by >-€0.001.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is -€0.07.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 207,132,570 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of -€0.068 in its last earnings report, missing expectations of -€0.067. Following the earnings report the stock price went down -2.11%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Among the largest hedge funds holding Biocryst Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Biocryst Pharmaceuticals’s shares valued at 62M.
---
BioCryst Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€15.44 (118.36% Upside)
€15.44 (118.36% Upside)
Blogger Sentiment
Bullish
DE:BO1 Sentiment 90%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.06%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
---
BO1 Company Deck
---
BO1 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth for Orladeyo, successful addition of new prescribers, and significant progress in clinical trials and financial performance, indicating positive momentum. However, challenges remain with the Medicare paid rate and potential royalty impacts. Overall, the positive developments significantly outweigh the challenges.Read More>---
BO1 Stock 12 Month Forecast
Average Price Target
€15.44
▲(118.36% Upside)
Technical Analysis
Best Analysts Covering BO1
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+4.43%
assigned a buy rating 2 months ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +4.43% per trade.
---